Progression-free survival was slightly , but significantly , improved in the ombrabulin group compared with the placebo group ( median @ months -LSB- @ % CI @-@ -RSB- vs @ -LSB- @-@ -RSB- months ; hazard ratio @ -LSB- @ % CI @-@ -RSB- ; p = @ ) .